Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Brand drug

Taytulla(Norethindrone-E.Estradiol-Iron)AbbVie Inc. logoABBV

Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by AbbVie Inc.

$19K

Medicare cost, 2024

Medicare drug plans spent $19,163 on Taytulla (norethindrone-e.estradiol-iron) in 2024, for 45 prescriptions and refills. Spending fell 37% from 2023 to 2024. It is made by AbbVie Inc. (ABBV).

Medicare cost, 2024

$19K

-36.9% from 2023

Prescriptions

45

$425.84 per claim

Patients

-

13 prescribers

Total spending, 2024

$19K

- per patient

Questions and answers

How much does Medicare spend on Taytulla?

Medicare prescription drug plans paid $19K for Taytulla in 2024, for 45 prescriptions and refills to - patients (down 36.9% from 2023). The average cost per claim was $425.84.

Which state spends the most on Taytulla?

Kansas had the highest Medicare cost for Taytulla in 2024: $3,323 for 13 claims.

Who prescribes Taytulla the most?

Douglas S Gleason, obstetrics & gynecology in Topeka, KS, had the highest Medicare cost for Taytulla in 2024: 13 claims costing $3,323.

Who makes Taytulla?

Taytulla is made by AbbVie Inc. (ABBV), listed in the Medicare spending data as Allergan Inc..

Spending over the years

Medicare spending by year

All plans and makers

Prescriber data: cost by year

Medicare spending on Taytulla was $19K in 2024, after a high of $75K in 2020.

By state

Where the prescribers practice, 2024

Medicare cost by state

States with the highest cost

Top prescribers of Taytulla, 2024

By Medicare drug cost

PrescriberTypeClaimsPatientsCost
Douglas S Gleason Topeka, KSObstetrics & Gynecology13Under 11$3,323

Prescriber data by year

YearPrescribersClaimsPatientsCost
2022177316$30K
2023166513$30K
20241345-$19K

Makers, 2024

Spending by manufacturer as listed in the spending data

ManufacturerClaimsSpending
Allergan Inc.ABBV logoABBV45$19K

More drugs: Medicare drug spending and the Prescriptions view.

Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.

LinkedInLinkedInXXYouTubeYouTube